Bigfoot Biomedical

Bigfoot Biomedical, Inc. is a medical technology startup headquartered with almost 130 employees as of 2019, in Milpitas, California.[1] It is founded by Jeffrey Brewer, Bryan Mazlish, and Lane Desborough.[2][3]

History

The company began in 2011 when founder Bryan Mazlish’s son was diagnosed with type 1 diabetes. Mazlish developed a control algorithm to drive the first automated artificial pancreas device for his wife and son.[4][5]

In late 2014, Mazlish joined with Brewer and Desborough to form Bigfoot Biomedical in order to scale and commercialize the technology.[5][6]

In January 2017, it was reported that Bigfoot Biomedical had received an investment from the Juvenile Diabetes Research Foundation (JDRF).[7]

In June 2017, the team from Patients Pending LTD, makers of the Timesulin smart insulin pen, joined Bigfoot Biomedical to lead the development of a smart pen solution for people utilizing multiple daily injections to manage their diabetes.[8]

Acquisitions

In May 2015, Bigfoot acquired the assets of Asante Solutions, former manufacturer of the Snap insulin pump. In June 2015, Bigfoot announced a development agreement with Dexcom, securing the technology needed for the continuous glucose monitoring component of the system.[9]

In June 2017, Bigfoot acquired London-based startup Patients Pending, LTD to assist with the development of an insulin pen product.[10][11]

Development timeline

Bigfoot Biomedical’s first clinical trial[12] enrolled its first patients in 2016.[13][14] In December 2017, the company closed a Series B funding round and announced plans to begin clinical trials for an automated insulin delivery system in 2018.[11][15]

gollark: It produced a *great* result for "no u", though.
gollark: Blame the DDG API.
gollark: ++search no u
gollark: ++help
gollark: !help

References
  1. "Bigfoot CEO talks data-driven diabetes care and becoming a service company". MedTech Dive. Retrieved 2020-04-17.
  2. Smith, Peter Andrey (22 February 2016). "A Do-It-Yourself Revolution in Diabetes Care". The New York Times. Retrieved 6 April 2016.
  3. Knutson, Ryan (8 June 2015). "Computer Experts Deliver Insulin to Diabetic Kids". The Wall Street Journal. Retrieved 6 April 2016.
  4. "No More Sleepless Nights: The Relationship Between Innovative Therapies for Parents of Children with Type 1 Diabetes". Welkin Health. Retrieved 11 August 2017.
  5. Hurley, Dan. "Artificial Pancreas Makers Race to Market". Discover Magazine (May 2016). Retrieved 6 April 2016.
  6. Evans, Rogene. "Ones to Watch, ten companies we're keeping an eye on". Medical Design and Outsourcing. Retrieved 28 September 2016.
  7. "Bigfoot Biomedical gets investment from JDRF's new venture fund for smart automated insulin delivery system". MobiHealthNews. 2017-01-30. Retrieved 2017-10-16.
  8. "Bigfoot Biomedical acquires Timesulin". 2017-06-08.
  9. "Bigfoot Biomedical Ups its Game Through Recent Acquisition and Partnership". Medical Product Outsourcing. 8 June 2015. Retrieved 6 April 2016.
  10. Hoskins, Mike. "NEWS: Bigfoot Closed Loop to Use Next-Gen Abbott FreeStyle Libre". DiabetesMine. Healthline. Retrieved 9 August 2017.
  11. Baum, Stephanie (2017-12-21). "Bigfoot Biomedical closes $37M Series B as it prepares for clinical trials of insulin delivery tech". MedCity News. Retrieved 2019-09-06.
  12. Hoskins, Mike. "NEWSFLASH: Bigfoot to Kick Off Closed Loop Clinical Trial!". Healthline.
  13. Crotti, Nancy. "Artificial Pancreas Race Includes a Motivated Underdog". QMed. Retrieved 28 September 2016.
  14. Falconer, Sara. "I Was Hooked Up to Bigfoot's Artificial Pancreas". Insulin Nation. Retrieved 28 September 2016.
  15. Thompson, Mary. "Bigfoot and Abbott: A Match Made in Heaven? An Interview with Bigfoot Biomedical CEO Jeffrey Brewer" (PDF). The MedTech Strategist. Innovation In Medtech, llc. Archived from the original (PDF) on 10 August 2017. Retrieved 9 August 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.